Studies which have separately studied bevacizumab for recurrent gliomas and bevacizumab for
newly-diagnosed glioma have shown good results and the regimens have been well-tolerated by
patients. This study seeks to investigate the use of bevacizumab with the standard therapy
(radiation therapy and temozolomide) in newly diagnosed patients, followed by bevacizumab and
temozolomide with the continuation of bevacizumab following progression. Two critical
questions remain- the role of bevacizumab maintenance and bevacizumab at the time of
progression in a patient previously treated with bevacizumab at the time of initial
diagnosis.